Skip to content

Harrow HROW Deferred Tax Assets, Net of Valuation Allowance

Deferred Tax Assets, Net of Valuation Allowance at other companies

Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
Warby Parker logo
Warby ParkerWRBY

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%
Enterprise value$1.81B+13.8%
P/S5.9×+0.5×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsNet.

The official record: Harrow’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's deferred tax assets, net of valuation allowance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's deferred tax assets, net of valuation allowance?
Harrow (HROW) reported deferred tax assets, net of valuation allowance of $34.98M in Q4 2025.
How has Harrow's deferred tax assets, net of valuation allowance changed year-over-year?
Harrow's deferred tax assets, net of valuation allowance increased by 62.6% year-over-year, from $21.51M to $34.98M.
What is the long-term trend for Harrow's deferred tax assets, net of valuation allowance?
Over 5 years (2020 to 2025), Harrow's deferred tax assets, net of valuation allowance has grown at a 17.2% compound annual growth rate (CAGR), from $15.84M to $34.98M.